Pipeline
Gamma Delta T
Gamma delta (γδ) T cells are a unique subset of T lymphocytes that play a pivotal role in immune surveillance and anti-tumor immunity. Unlike conventional αβ T cells, γδ T cells recognize and eliminate cancer cells in an MHC-independent manner, making them a promising candidate for allogeneic cell therapy. SL Bio’s unmodified γδ T cell platform is designed to leverage the natural cytotoxicity of these cells to target a broad spectrum of solid and hematologic malignancies, offering a novel and effective approach to cancer treatment.
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-GD001
Glioblastoma
SL-GD002
Pancreatic cancer
SL-GD003
AML
SL-GD001 (GBM)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-GD001
Glioblastoma
Glioblastoma (GBM) is the most aggressive and common primary brain tumor, known for its rapid progression, resistance to standard therapies, and highly immunosuppressive tumor microenvironment. SL-GD001 is an unmodified allogeneic gamma delta (γδ) T cell therapy designed to enhance the immune system’s ability to eliminate GBM by overcoming its immunosuppressive barriers. Our strategy seeks to offer a novel immunotherapy for GBM patients who have exhausted conventional treatment options. Currently in preclinical and early clinical development, SL-GD001 is advancing toward clinical evaluation, with a focus on safety, optimal dosing, and therapeutic efficacy.
SL-GD002 (Pancreatic Cancer)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-GD002
Pancreatic cancer
SL-GD002 is our unmodified allogeneic gamma delta T cell product designed for the treatment of pancreatic cancer, a highly aggressive malignancy with limited therapeutic options and poor prognosis. This innovative therapy targets the immunosuppressive tumor microenvironment, aiming to enhance anti-tumor immunity and improve patient outcomes. SL-GD002 is intended for patients who have shown resistance to standard treatments, including chemotherapy and immune checkpoint inhibitors, providing a potential alternative that may delay disease progression or complement existing therapies. We are actively preparing for clinical trials to evaluate the safety and efficacy of SL-GD002, with the ultimate goal of advancing this novel immunotherapy towards regulatory approval and commercialization.
SL-GD003 (AML)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-GD003
AML
SL-GD003 is our unmodified allogeneic gamma delta T cell product designed for the treatment of Acute Myeloid Leukemia (AML), a rapidly progressing hematologic malignancy characterized by uncontrolled proliferation of immature myeloid cells, leading to bone marrow failure and severe systemic complications. This innovative therapy is intended for patients who exhibit resistance to standard chemotherapy, aiming to provide an alternative treatment option that may delay or even eliminate the need for bone marrow transplantation. We are actively preparing for clinical trials to assess the safety and efficacy of SL-GD002, with the ultimate objective of advancing this novel immunotherapy towards regulatory approval and commercialization.